TrialThoracic cancer2025

Three-Year Follow-Up of the Phase II Trial for Resectable Non-Small-Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD-NeoFOUR Trial.

Zhiyuan Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.